Quantitative Study of Impurities in Bedaquiline Fumarate: Identification and Characterization of Its Three Degradation Products Using HPLC, LC/ESI-MS, and NMR Analyses

Abstract

The study aimed to establish a high-performance liquid chromatography (HPLC) method for the quantitative analysis of the related substances of bedaquiline fumarate. Nuclear magnetic resonance and mass spectrometry were used for characterization and assay. A chromatographic method was used for separation. The conditions used were: gradient elution system composed of methanol 0.01mol/L KH₂PO₄ and 0.01 mol/L K₂HPO₄ (pH = 4.1) with a flow rate of 1 mL/min, at 224 nm as the detection wavelength. In this study, three degradation products of bedaquiline fumarate have been disclosed for the first time. The related impurities and degradation products of the drug were well separated. The method provided linear responses within the concentration range, which varied from 0.20 to 10.08 μg/mL with limits of detection of 0.10 μg/mL and limits of quantification of 0.20 μg/mL. The mean percent recovery varied between 91.64 and 105.89%. The method was validated for other parameters such as specificity, stability, and robustness. This method was validated and worked well for the impurity studies and quality control analysis of the laboratory-prepared samples of bedaquiline fumarate.

Keywords

bedaquiline fumarate - HPLC - related substances - method validation

Publikationsverlauf

Eingereicht: 06. Juli 2022

Angenommen: 28. Januar 2023

Artikel online veröffentlicht:
16. März 2023

• References

• 1 Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother 2014; 48 (01) 107-115
• 2 Deng Q, Xiao CL. The progress of new anti-tuberculosis drugs. [in Chinese]. Zhongguo Xin Yao Zazhi 2019; 28 (13) 1567-1573
• 3 Chen H, Wu NN, Hu WH, Yang ZJ. Research progress of new targets for antituberculosis agents. Zuo Wu Xue Bao 2020; 42 (03) 286-292
• 4 Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res 2013; 3 (01) 1-2
• 5 Preiss L, Langer JD, Yildiz Ö. et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv 2015; 1 (04) e1500106
• 6 Kundu S, Biukovic G, Grüber G, Dick T. Bedaquiline targets the ε subunit of mycobacterial F-ATP synthase. Antimicrob Agents Chemother 2016; 60 (11) 6977-6979
• 7 Hards K, McMillan DGG, Schurig-Briccio LA. et al. Ionophoric effects of the antitubercular drug bedaquiline. Proc Natl Acad Sci U S A 2018; 115 (28) 7326-7331
• 8 Sebastian S, Singh S, Polavarapu S, Veera U. . Process for the preparation of bedaquiline fumarate [in India]. IN Patent 201941005058. August, 2020
• 9 Makadia P, Rajput S. Evaluation of physicochemical stability and degradation kinetics of bedaquiline in hydrolytic solutions of different pH. Futur J Pharm Sci 2021; 7: 88
• 10 Vanavi PJ, Rajput SJ. Separation and characterization of novel degradation and process related impurities of bedaquiline bulk drug. J Chromatogr Sci 2022; 60 (07) 678-691
• 11 Baksam VK, Nimmakayala S, Pocha VR, Gouri B, Shandilya S, Kumar P. Separation and characterization of the related substances of bedaquiline fumarate using HPLC and spectral methods. J Chromatogr Sci 2022; 60 (09) 848-858
• 12 Zeng W, Qiao CL, Guo YB, Yang B. A method for separating and analyzing optical isomers of Bedaquinoline [in Chinese]. CN Patent 201710670318.4. February, 2019
• 13 Alffenaar JW, Bolhuis M, van Hateren K. et al. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2015; 59 (09) 5675-5680